See Graham's ranking
4.0
Pfizer Inc. is a global biopharmaceutical company operating in the Healthcare sector. It was founded by German immigrants Charles Pfizer and Charles F. Erhart.
Focused on the research, development, manufacturing, and commercialization of medicines, the company also plays a major role in the production of vaccines across both developed and emerging markets.
Listed in the Healthcare sector, under the Biotechnology and Pharmaceuticals industry, Pfizer plays a critical role in the global pharmaceutical landscape by delivering innovative solutions across multiple therapeutic areas.
The company generates most of its revenue through the sale of proprietary biopharmaceutical products, and to a lesser extent, through strategic partnerships and alliances aimed at co-developing new treatments.
Pfizer’s products are distributed globally to wholesalers, hospitals, clinics, pharmacies, and government agencies, serving customers in more than 125 countries.
Its business is organized into six core operating areas:
- Internal Medicine: therapies targeting cardiovascular, metabolic diseases, and chronic pain.
- Oncology: development of biologics, immunotherapies, and biosimilars for various cancers.
- Hospital: production of sterile injectables and anti-infectives, as well as contract manufacturing via Pfizer CentreOne.
- Vaccines: development of immunizations for diseases such as COVID-19, meningitis, and pneumococcal infections, serving all age groups.
- Inflammation and Immunology: treatments for chronic inflammatory diseases and autoimmune disorders.
- Rare Diseases: advanced therapies for conditions such as amyloidosis and hemophilia.
Pfizer employs thousands of professionals worldwide and maintains a robust infrastructure for research, manufacturing, and global distribution, ensuring delivery of essential medications to millions of patients.
The company’s shares are traded on the New York Stock Exchange (NYSE) under the ticker PFE.
History and Founding of Pfizer Inc.
Pfizer was founded in 1849 in Brooklyn, New York, by German immigrants Charles Pfizer and Charles F. Erhart, initially to produce an antiparasitic compound known as santonin.
From its early years, the company stood out for its innovation and ability to adapt to market needs—most notably by supplying analgesics and antiseptics to the U.S. military during the American Civil War, which accelerated its early growth.
In the following decades, Pfizer expanded internationally, establishing offices in countries such as Belgium, Brazil, Canada, Cuba, Mexico, Panama, Puerto Rico, and the United Kingdom—laying the foundation for its global presence.
Between the 1950s and 1970s, the company heavily invested in research and development, launching new medications and expanding across international markets.
From the 2000s onward, Pfizer pursued a growth strategy driven by mergers and acquisitions, including:
- Warner-Lambert (2000): expanding its cardiovascular drug portfolio.
- Pharmacia and Upjohn (2002): strengthening its oncology and hormone therapy divisions.
- Wyeth (2009): expanding into vaccines and biotechnology.
- Medivation (2016): enhancing its presence in the oncology market.
In recent years, Pfizer gained global recognition for developing one of the first effective COVID-19 vaccines, in partnership with BioNTech, solidifying its leadership in vaccine development.
Between 2020 and 2024, the company continued to invest in innovation, expanding its pipeline of advanced therapies, strengthening its footprint in emerging markets, and improving infrastructure to meet global demand for effective healthcare solutions.
Today, Pfizer remains focused on sustainable growth, ongoing innovation, and expanding its product portfolio—maintaining its position as one of the largest and most influential pharmaceutical companies in the world.
Additional Information
The Company Pfizer Inc. (United States), is listed on NYSE with a market cap of $ 139.89 Billions, having an equity of $ 93.10 Billions.
With a total of 78.500 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.
In the last 12 months the Company had a revenue of $ 62.79 Billions, which generated a profit in the amount of $ 9.83 Billions.
As for its main indicators, the Company has a P/E ratio of 14.23, a P/BV ratio of 1.50 and in the last 12 months the dividend yield of PFE was at 6.95%.
The Company is traded internationally through the ticker PFE.
